ARHGEF2 is a Rho/Rac guanine nucleotide exchange factor that activates RhoA signaling pathways and plays diverse roles in cellular processes and disease. The protein functions as a key activator of RhoA-dependent pathways, with its activity regulated through microtubule-mediated sequestration and release mechanisms 1. In cancer biology, ARHGEF2 demonstrates complex roles across different tumor types. In colorectal cancer, YTHDF1 promotes ARHGEF2 translation through m6A-mediated mechanisms, enhancing RhoA signaling and supporting tumor growth and metastasis 2. Conversely, in prostate cancer, ARHGEF2 is directly suppressed by androgen receptor signaling, but androgen deprivation therapy restores ARHGEF2 expression, contributing to treatment resistance and neuroendocrine differentiation 3. The protein also regulates cellular metabolism, as demonstrated in pancreatic cancer-associated fibroblasts where ARHGEF2 controls macropinocytosis through CaMKK2/AMPK signaling, supporting both stromal cell fitness and tumor cell survival 4. In immune function, ARHGEF2 forms regulatory complexes with CCDC88B and RASAL3 that modulate dendritic cell migration and immune responses in neuroinflammation and colitis 5. Additionally, ARHGEF2 participates in oncogenic fusion proteins, as seen in ARHGEF2-NTRK1 fusions identified in various cancers including glioblastoma and histiocytosis 67.